Natera Oncology Portfolio

Optimizing the management of patients with solid tumors using a tumor-informed approach

Natera_HorizonPanoramaVasisteraCombo FINAL

Webinar: Changing the paradigm for colorectal cancer - Clinical practice & drug development

Many ongoing studies aim to improve treatment and outcomes for early-stage colorectal cancer, including guiding adjuvant chemotherapy decisions and bringing targeted therapies and immunotherapies into

Webinar and Panel Discussion: New data on how ctDNA is evolving oncology patient management and drug development

In the Driver's Seat with Signatera

How can real-world clinicogenomics data accelerate drug development?

Build early evidence that your investigational drug is working

Monitoring immunotherapy treatment response with ctDNA Real-world applications of Signatera in melanoma

See how Beth worked with her doctor to use Signatera to help guide her cancer treatment plan

2.11 Webinar (slides and video) (circulate japan LP)

SignaCase: Treatment response monitoring in Stage IV EGFR+ NSCLC

Signatera is a personalized tumor-informed test that can help doctors detect cancer progression earlier. Learn how Signatera helped JoAnn and her family stay confident and positive throughout her lung

Real-world clinical applications of Signatera in IO monitoring

Real-world clinical applications of Signatera in IO monitoring direct

2.11 Webinar (slides and video)

Using ctDNA to guide the management of GI cancers

Latest Data in Breast Cancer Response Monitoring and Relapse Prediction

Jeff’s Story: See how Signatera “takes away the question marks” to help take control of cancer

SignaCase: A Case Review: Long-term stable disease on immunotherapy

Innovations in Clinical Trial Design with ctDNA MRD